Comprehensive Summary: Acute Decompensation, Non-Acute Decompensation, and ACLF in Patients with Cirrhosis
Presenter: Professor Paolo Angeli, MD | University of Padova, Italy | Chair, EASL-CLIF Consortium
1. Main Clinical Topics Discussed
- Pathophysiology of hepatic decompensation and organ failure in cirrhosis
- Definition and diagnostic criteria for acute decompensation (AD), non-acute decompensation, and Acute-on-Chronic Liver Failure (ACLF)
- Role of systemic inflammation, oxidative stress, and portal hypertension as drivers of disease progression
- Immunometabolic dysfunction in ACLF
2. Key Learning Points, Guidelines, and Recommendations
Pathophysiology: Beyond Portal Hypertension
- Historically, portal hypertension was considered the sole driver of decompensation via splanchnic arterial vasodilation, activation of vasoconstrictors, and sodium/water retention
- This model is now considered incomplete for three reasons:
- Progressive vasoconstrictor activation is not uniformly observed in advanced disease
- Modulating these factors (vasoconstrictors, albumin, or both) has not yielded significant clinical improvement in complication rates or one-year survival
- ACLF, a distinct syndrome with high short-term mortality, can develop at any stage of cirrhosis and is not explained by portal hypertension alone
Three Drivers of Decompensation
1. Portal hypertension (established mechanism)
2. Systemic inflammation — a powerful, early driver present even in Grade 1 ascites; intensifies progressively toward refractory ascites and ACLF
3. Oxidative stress — mediated by oxidized albumin (human mercaptoalbumin 1 and 2); accumulates progressively with disease severity
Unified Pathophysiological Model
- Bacterial translocation (primary initiating event) → systemic inflammation + oxidative stress → cardiovascular dysfunction → reduced effective circulating volume → ascites and organ failure
- Pro-inflammatory cytokines (e.g., IL-6) directly upregulate sodium channel gene expression in the renal collecting duct, independently promoting sodium retention
- Inflammation and oxidative stress create a vicious cycle, further worsening portal hypertension and liver failure → increased bacterial translocation
Mechanisms of Organ Failure
- Innate immune activation by PAMPs and DAMPs → pro-inflammatory cytokine release
- Cytokines induce lipolysis, glycolysis, and proteolysis → substrate diversion away from peripheral organ cells → cellular energy deficit
- "Friendly fire" cascade:
- Overproduction of nitric oxide (NO) and reactive oxygen species (ROS) → splanchnic vasodilation, cirrhotic cardiomyopathy
- NO and ROS → mitochondrial dysfunction → impaired glycolysis and beta-oxidation of fatty acids → further energy deficit
- Mitochondrial dysfunction extends to immune cells → impaired antibacterial activity (immunometabolic dysfunction)
3. Specific Clinical Data, Statistics, and Study Results
- EASL-CLIF ACLF Definition: Cirrhosis + acute decompensation + organ failure + 28-day mortality >15%
- Key differences between EASL-CLIF, APASL, and AASLD criteria:
- APASL: includes non-cirrhotic chronic liver disease; does not recognize bacterial infections as precipitants
- AASLD: differs primarily in organ failure definition criteria
- 62 genes identified as differentially expressed between patients who develop organ dysfunction/ACLF versus those with stable chronic liver disease; most relate to upregulation of innate immune response
- A 28-gene score derived from this analysis outperforms conventional clinical scores (e.g., MELD) in predicting transition from acute decompensation to ACLF
- Inflammatory cytokine profiling (Types 1, 2, and 3 inflammation) differs significantly across disease stages:
- IL-6 elevated when bacterial infection is the precipitant
- **TNF